Neoadjuvant Anti-Angiogenesis Therapy for Prostate Cancer
Abstract
This proposed clincial trial targets men at risk for recurrence after prostatectomy by treating systemic micrometastatic disease in addition to local. Thus far, anti-angiogenesis therapy is safe in men undergoing radical prostatectomy and postulated changes in angiogenic factors as well as grade and stage have been observed.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2004
- Accession Number
- ADA437213
Entities
People
- Mitchel H. Sokoloff
Organizations
- University of Chicago